Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma.
M
M
Lapecorella
M
M
Napolitano
M
M
Tudini
G
G
Bruera
A
A
Lucchesi
A V
AV
Giordano
G
G
Mariani
E
E
Ricevuto
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000150:complications* / Q000188:drug therapy*; D002908:Chronic Disease; D005169:Factor VIII / Q000008:administration & dosage; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy; D006509:Hepatitis B / Q000150:complications; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D000077157:Sorafenib; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D005169:Factor VIII; D000077157:Sorafenib